Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Psilocybin as an Adjunctive Treatment for OUD Patients on Methadone
NCT06796062Phase 2Recruiting
- Sponsor
- NYU Langone Health
- Start
- Dec 2025
- Primary completion
- Feb 2029
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of psilocybin in opioid use disorder (OUD) (5 arms), sponsored by NYU Langone Health. Primary endpoints: The number of weeks during the 24 week follow-up period with no illicit opioid use, Number of adverse events at 24 weeks and 4 more. Started Dec 2025; status: recruiting.
02
Drugs
psilocybin
03
Conditions
opioid use disorder (OUD)
Beyond the preview
Go deeper on NCT06796062.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06796062.